Department of Medicine
Faculty Profiles by Division

Department of Medicine

Faculty Profiles

[Return To Index page]
photo Anuradha Krishnamurthy, MBBS, FRCPC

Hematology/Oncology

Email: krishnamurthya2@upmc.edu

Phone: 412-623-3283

Contact
Office: 5150 Centre Avenue, 5th floor
Room 567
Pittsburgh, PA 15232
 
Phone: 412-623-3283
Fax:
E-mail: krishnamurthya2@upmc.edu
Administrative Assistant:
Lois Malehorn
Address: 5150 Centre Avenue, 5th floor
Pittsburgh, PA 15232
Email: malehornlm@upmc.edu
Phone: 412-648-6589
Fax: 412-648-6575
Education and Training
Education
Bachelor of Medicine, Sydney Medical School, University of Sydney, 2010
Bachelor of Science, University of Toronto, Toronto, Canada
Training
Medical Oncology Fellowship, Kingston General Hospital, Queen's University, 2016
Internal Medicine, The Ottawa Hospital, University of Ottawa, 2014
Research Interest
I believe that drug development and translational research should be an integral part of cancer care and hence, I completed a two-year drug development fellowship at the University of Colorado. During my fellowship, I have been involved in writing early phase clinical trial protocols, reviewing industry written protocols, participating in safety meetings and enrolling patients on clinical trials. I had the privilege of attending the prestigious ASCO/AACR Methods in Clinical Cancer Research Workshop in 2017 where I had the opportunity to expand my abilities to develop clinical trials.

I was involved in a phase I clinical trial in Colorado that combined selumetinib, a MEK inhibitor with Cyclosporin A, a Wnt inhibitor. Wnt pathway dysregulation is commonly seen in colorectal cancer and this study looked at the toxicities and potential anti-tumor effects of the combination of Wnt and MEK inhibition. Results of this study have been promising. I have also been involved in the development of an early phase clinical trial combining a PD-1 inhibitor (Pembrolizumab) with a MEK inhibitor (Binimetinib) and a VEGF inhibitor (Bevacizumab). This study looks at the effectiveness of combining an immune checkpoint inhibitor with the immune modulatory effects of MEK AND VEGF inhibition.
Clinical Interest
My clinical interests are in the diagnosis and multidisciplinary management of gastrointestinal (GI) cancers to provide comprehensive cancer care to all my patients. There is an unmet need for better treatment strategies for patients with advanced GI cancers who have exhausted standard therapy options. Hence, my interest in developing novel treatment options through phase I clinical trials.